|
To receive daily emails from Breaking Christian News to your inbox CLICK HERE
Drug Developed in Israel Saves 47 of 50 Severe Covid Patients in TrialBonus BioGroup says its MesenCure experimental treatment resulted in 94% survival rate of trial subjects and cut hospitalization time in half.
Study results, soon to be published, show MesenCure treatment reduced study participants' hospitalization period by about half compared to a control group. All these patients had life-threatening pneumonia and respiratory distress caused by Covid-19. The data shows that MesenCure treatment reduced mortality by about 70% compared with the control group. Only two of the first 30 severe Covid-19 patients treated with MesenCure died due to Covid-19 or its complications, while 14 of 60 similar patients in the control group died. MesenCure treatment shortened the hospitalization period of severe Covid-19 patients by eight days on average, a reduction of 45% relative to the control group. The experimental group included women and men aged 41.4 to 77.4. About 77% of the severe Covid-19 patients treated in three hospitals with MesenCure had one or more risk factors for poor prognosis: hypertension, hyperlipidemia, obesity and Type 2 diabetes. Most were treated during the fourth Covid-19 wave in Israel, dominated by the Delta strain. The control group received the current standard of care — anti-inflammatory drugs in combination with steroids. This regimen, according to Bonus BioGroup, reduces mortality in hospitalized Covid-19 patients only slightly, from 25.8% to 21.8%, indicating that MesenCure is four times more effective. "We are proud of our success in leading the world to be a safer place by developing a medication for severe Covid-19 patients, thereby dramatically reducing the threat to their lives," said Dr. Shai Meretzki, CEO of Bonus BioGroup. "In less than two years from the epidemic outbreak, we are the first in the world to report an effective and significant treatment for severely ill patients." According to a statement from Bonus BioGroup, an independent expert committee confirmed the findings of the Phase II clinical trial of MesenCure and recommended continuing toward Phase III. Meretzki told the Jerusalem Post that the company will apply for emergency use approval from European and US regulatory agencies. Subscribe for free to Breaking Christian News here
To receive daily emails from Breaking Christian News to your inbox CLICK HERE
Other Recent Articles from Breaking Christian News [Watch] JD Vance Ventures Onto 'The View,' Serves Up an Unforgettable Schooling School District Pays $95K to Settle Lawsuit After Painting Over Bible Verse Tribute to Charlie Kirk Is MLB Treating Christians Differently? Senator Hawley Demands Answers Hundreds of Thousands of Antidepressants Recalled Over Potential Cancer Risk Feds Name Five Individuals Charged in UFC Freedom 250 Terror Plot Video: Iran Soccer Fans Defy FIFA Autocrats and Fly 'Lion & Sun' Pre-Islamic Regime Flags Good News: Nearly 60 Planned Parenthood Facilities Have Shut Down Since Trump Took Office Illinois Man Receives Prison Sentence for Killing Unborn Baby With Abortion Pills Louisiana Dad Poisons His Daughter with Abortion Drug in Latest Mifepristone Horror Story Major League Baseball Warns Christian Players Not to Put Bible Verses on Caps Kennedy and Rollins Make Huge Announcement About Ridglan Farms and Animal Testing Prayer Alert: 8 Killed in B-52 Bomber Crash at Edwards Air Force Base in California 60,000 Christians Rally for Jesus in One of the World's Most Secular Countries New Research: The Big Questions on Teens' Minds Today 'Help Me!': Botched Euthanasia Exposes the Horrific Reality Behind 'Medical Aid in Dying' A New Study Just Confirmed the Left's Worst-Kept Secret Search the Articles Archives |
All articles on this site and emails from BCN are copyrighted property of Breaking Christian News. Permission is given to link to, or share a BCN story if proper attribution is given to both the original writer and summarizer of the story. Breaking Christian News 2005-2019. All Rights Reserved.
Breaking Christian News is a division of Elijah List Publications, Inc. All Rights Reserved
Disclaimer: Articles and links, as well as the source articles linked to; do not necessarily reflect the opinion of Breaking Christian News.
| Home | Store | Subscribe | Facebook | Article Archive |